


Halogenative Difluorohomologation of Ketones

Oleg V. Fedorov, Mikhail D. Kosobokov, Vitalij V. Levin, Marina I. Struchkova, and Alexander D. Dilman*

N. D. Zelinsky Institute of Organic Chemistry, 119991 Moscow, Leninsky prosp. 47, Russian Federation

S Supporting Information

ABSTRACT: A method for the difluorohomologation of ketones accompanied by halogenation of a C–H bond is described. The reaction involves silylation, difluorocarbene addition using $\text{Me}_3\text{SiCF}_2\text{Br}$ activated by a bromide ion, and halogenation of intermediate cyclopropanes with *N*-bromo- or *N*-iodosuccinimide. The whole process is performed without isolation of intermediates. The resulting α,α -difluoro- β -halo-substituted ketones can be readily converted into fluorine containing pyrazole derivatives and oxetanes.



INTRODUCTION

α,α -Difluoroketones represent an important subclass of organofluorine compounds, useful for medicinal chemistry^{1,2} and other fields.³ Due to significant the electron-withdrawing effect of two fluorine atoms, the carbonyl group can react with water to form hydrate adducts. The hydration not only alters the polarity of the starting molecule but also changes the shape of the carbonyl functionality from planar to tetrahedral. The hydrate adducts can mimic the transition state of peptide hydrolysis thereby serving as inhibitors of proteases. This phenomenon has been exploited for the identification of inhibitors of various enzymes.^{2a–c} Moreover, other mechanisms of biological activities of α,α -difluorinated carbonyl compounds have been discovered.^{2d,e}

Conventional methods for the synthesis of α,α -difluoroketones involve functionalization of the difluorocarbonyl fragment⁴ or electrophilic fluorination of parent ketones and their derivatives⁵ (Scheme 1). Recently, we proposed a concept for difluorohomologation of ketones **1** based on generation of


silyloxy-substituted cyclopropanes **2** followed by their protonation.⁶ Herein we report that cyclopropanes **2** may undergo halogenation leading to β -halogen-substituted α,α -difluoroketones **3** and demonstrate the utility of the latter for the preparation of other *gem*-difluorinated products.

The halogenation of nonfluorinated cyclopropanols and their derivatives was well documented,⁷ and frequently employed in combination with subsequent halogen elimination to afford α,β -unsaturated ketones.^{7,8} While halogen elimination is facile in nonfluorinated series,⁹ it is not feasible for products **3** due to the presence of two fluorine atoms. However, for halogenation of fluorinated cyclopropyl ethers, the data available in the literature are scarce. Thus, in a single example, the reaction of a cyclopropane, derived from difluorocarbene addition to 2-methoxypropene, with an excess of bromine in water was reported to afford a tribromo-substituted product (the primary ring-opened product underwent subsequent dibromination at the methyl group).¹⁰ On the other hand, perfluorinated cyclopropyl ethers reacted with bromine at very harsh conditions (temperatures exceeding 150 °C, long reaction times).¹¹


Cyclopropanes **2** can be accessed by difluorocarbene addition to silyl enol ethers. However, the limited stability of cyclopropanes **2** is a key problem determining the scope of their applications.⁶ Indeed, compounds **2** are prone to transformation into α -fluoroenones, and this process can proceed either at elevated temperatures¹² or under neutral or basic conditions even at room temperature.¹³ Conventional chromatographic isolation of **2** may also be problematic.^{6a} Therefore, compounds **2** must be generated under the mildest conditions possible and subsequently immediately employed, preferably in the same reaction flask.

Scheme 1. Synthesis of α,α -Difluoroketones

Conventional methods



Our approach



RESULTS AND DISCUSSION

A wide variety of reagents for the generation of difluorocarbene have been described in the literature.¹⁴ However, a silicon reagent, (bromodifluoromethyl)trimethylsilane ($\text{Me}_3\text{SiCF}_2\text{Br}$), was selected for our study due to the following reasons: (a) it can

Received: April 22, 2015

Published: May 12, 2015

effect difluorocyclopropanation of alkenes under virtually nonbasic and anhydrous conditions;^{15,16} (b) it is an air-stable and easy-to-handle compound;¹⁷ (c) it is now commercially available from several suppliers, or can be prepared in one or two steps from readily available (trifluoromethyl)trimethylsilane.^{15a,17a}

Silyl enol ether **4a**, derived from *p*-bromoacetophenone, was selected as a model substrate. First, enol ether **4a** was converted into cyclopropane **2a** using Me₃SiCF₂Br and hexamethylphosphoramide (HMPA) according to a previously developed procedure,^{6a} followed by addition of bromine (Table 1).

Table 1. Preparation of Ketone **3a**


no.	conditions	2a:3a ^a	yield of 3a, % ^a
1	(a) TMSCF ₂ Br (2 equiv), HMPA (3 equiv), dioxane, rt, 2 h (b) Br ₂ (1.5 equiv), rt, 10 min	81:19	16
2	(a) TMSCF ₂ Br (2 equiv), HMPA (3 equiv), dioxane, rt, 2 h (b) NBS (1.5 equiv), rt, 10 min	75:25	13
3	(a) TMSCF ₂ Br (1.3 equiv), Bu ₄ NBr (0.2 equiv), dichloroethane, Δ, 2 h (b) NBS (1.3 equiv), rt, 10 min	—:100	60
4	(a) TMSCF ₂ Br (1.5 equiv), Bu ₄ NBr (0.2 equiv); MeCN, 80 °C, 1.5 h (b) NBS (1.3 equiv), rt, 10 min	—:100	89 ^b

^aDetermined by ¹⁹F NMR of reaction mixtures. ^bIsolated yield.

However, there was only 19% conversion of **2a** to **3a** within 10 min, which did not increase with time even upon mild heating (entry 1). The use of *N*-bromosuccinimide (NBS) gave a similar result (entry 2). Presumably, Lewis basic HMPA inhibits the bromination reaction.¹⁸ Then we switched to cyclopropanation conditions involving a bromide ion as an activator of the silicon reagent. It was reported that combination of Me₃SiCF₂Br with catalytic amounts (3 mol %) of Bu₄NBr works well at 110 °C for various alkenes.^{15a} In our case, the moderate stability of cyclopropane **2a** prompted us to employ lower temperatures with a concomitant increase of concentration of the bromide activator. When the reaction was performed in hot 1,2-dichloroethane (82 °C) using Me₃SiCF₂Br and 0.2 equiv of Bu₄NBr, the cyclopropane was formed in about 60% yield. Surprisingly, ¹⁹F NMR analysis indicated the formation of less reactive Me₃SiCF₂Cl, which likely originates from initial Br/Cl exchange between the bromide ion and dichloroethane followed by Br/Cl exchange between the appearing chloride ion and Me₃SiCF₂Br.¹⁹ Nevertheless, subsequent addition of NBS gave rapid conversion of **2a** into **3a** (entry 3). To exclude halogen exchange, acetonitrile was used as a solvent, with the cyclopropanation being complete within 1.5 h at 80 °C. After the reaction mixture cooled to room temperature, NBS was added and within 10 min **2a** was cleanly converted to product **3a** which was finally isolated in 89% yield (entry 4).

We also attempted chlorination of intermediate cyclopropane **2a** using *N*-chlorosuccinimide (NCS) (Scheme 2). Thus, when NCS was added to the cyclopropane generated from enol ether **4a** under typical conditions, only a brominated product along with Me₃SiCF₂Cl was observed by ¹⁹F NMR. Apparently, the

Scheme 2. Reactions Using NCS



combination of NCS and the bromide ion served as a brominating reagent along with the formation of a chloride ion, which reacted with excess Me₃SiCF₂Br. Unfortunately, use of the Me₃SiCF₂Cl/chloride/NCS combination provided a complex mixture containing significant amounts of unreacted cyclopropane **2a** along with its decomposition product, α-fluoroenone **5a**, and a minor amount of an expected chlorination compound.

Under the optimized conditions, a series of silyl enol ethers **4** were converted into bromo- or iodo-substituted products **3** employing NBS or NIS, respectively (Table 2). High yields of products were obtained from enol ethers derived from *p*-methoxyacetophenone, α-tetralone, and cyclohexanone.

Despite the fact that silyl enol ethers can be readily prepared from ketones,²⁰ we decided to perform the whole sequence of transformations of ketones into final products without the time-consuming isolation and purification of enol ethers. For this

Table 2. Synthesis of **3** from Silyl Enol Ethers **4**

substrate	X	product	yield of 3, % ^a
	Br		95
	I		82
	Br		97
	I		85
	I		80

^aIsolated yield.

purpose, ketones **1** were silylated using the chlorosilane/NaI/NEt₃ combination,^{20a} and the crude silyl enol ethers **4**, which were produced in virtually quantitative yields, were subjected to further reactions without purification (Table 3). This halogenative difluorohomologation worked well for acyclic and cyclic ketones affording final products **3** in good overall yields.

The key possible side reaction for the difluorohomologation process is the known rearrangement of cyclopropanes **2** into fluoroenones **5**¹² (Scheme 3). This rearrangement is favored by temperature and proceeds during the difluorocarbene addition step, whereas formed fluoroenones **5** undergo bromination at the next step leading to byproducts **6**, which are difficult to get rid of by flash chromatography. In particular, this side reaction was feasible for cyclopropanes **2** derived from acyclic alkyl substituted ketones (R² = Alk, entries 9 and 10). Similar processes were noted when difluorocarbene addition is disfavored by sterics (R¹ is *ortho*-substituted aryl group, entry 5) or electronic effects (R¹ contains *p*-nitro group, entry 6). For this reason, difluorocarbene addition for substrates **1f**, **1j** (entries 5, 9, 10) was carried out under slightly milder conditions (70 °C, 2.5 h). For *p*-nitroacetophenone **1g**, cyclopropanation was slow, and for complete conversion of silyl enol ether, higher loadings of Me₃SiCF₂Br and Bu₄NBr were used (entry 6). In the latter case, fluoroenone formation cannot be suppressed, and corresponding dibrominated byproduct **6a** was also isolated in 7% yield (see Scheme 3, structure **6**, R¹ = 4-NO₂C₆H₄, R² = H).

For silyl enol ether **4m**, derived from deoxybenzoin **1m**, cyclopropane **2m** was unstable under the cyclopropanation conditions (Scheme 4). As a result, the reaction of enol ether **4m** afforded fluoroenone **5m** and product **7**. The latter was formed from enone **5m** by nucleophilic addition of the CF₂Br anion at the carbonyl group.^{17d}

Compounds **3** may provide easy access to fluorine-substituted heterocycles, as was exemplified by reactions of ketone **3b** (Scheme 5). Thus, treatment of **3b** with phenylhydrazine and potassium carbonate afforded either pyrazoline **8** or pyrazole **9** depending on the reaction conditions. Addition of a hydride or a Grignard reagent to the carbonyl group furnished alcohols **10**, which under basic conditions were cyclized into *gem*-difluorinated oxetanes **11**. It should be pointed out that no methods have been described in the literature for the synthesis of 3,3-difluorinated oxetanes of this type, whereas with our approach these interesting products²¹ can be straightforwardly obtained starting from simple ketones.

In summary, a practical method for halogenative difluorohomologation of ketones is described. The process efficiency is determined by a difluorocarbene addition step, which is performed in warm acetonitrile by using a silicon reagent as a difluorocarbene source. At the same time, halogenation of the cyclopropanes occurs rapidly and selectively affording ring-opened products. The whole sequence can be conveniently performed without isolation of intermediate compounds. The products of halogenative difluorohomologation can be converted into valuable fluorine substituted heterocycles.

EXPERIMENTAL SECTION

General Methods. All reactions were performed under an argon atmosphere. Acetonitrile was distilled from CaH₂ and stored over MS 4A. Hexamethylphosphoramide (HMPA) and dimethylformamide (DMF) were distilled under vacuum from CaH₂ and stored over MS 4A. Column chromatography was carried out employing silica gel (230–400 mesh). Precoated silica gel plates F-254 were used for thin-layer analytical chromatography visualizing with UV and/or acidic aq.


Table 3. Synthesis of **3** from Ketones **1**

no.	substrate	X	product	yield of 3 , % ^a
		(a) Me ₃ SiCl (1.3 equiv), NaI (1.4 equiv), NEt ₃ (1.5 equiv), rt, 12 h (b) Me ₃ SiCF ₂ Br (1.5 equiv), Bu ₄ NBr (0.2 equiv), 80 °C, 1.5 h (c) NXS (1.3 equiv), rt, 10 min		
1		1a Br		3a 78
2		1b Br		3b 89
3		1b I		3c 80
4		1e Br		3g 92
5 ^b		1f Br		3h 65
6 ^c		1g Br		3i 56
7		1h Br		3j 91
8		1h I		3k 90
9 ^b		1i Br		3l 69
10 ^b		1j Br		3m 71
11		1c Br		3d 85
12		1d I		3f 77
13		1k I		3n ^d 76
14		1l Br		3o 96


^aIsolated yield based on ketone **1**. ^bCyclopropanation conditions: 70 °C, 2.5 h. ^cCyclopropanation conditions: Me₃SiCF₂Br (2 equiv), Bu₄NBr (0.3 equiv), 80 °C, 2 h. ^dMixture of isomers 5:1.

KMnO₄ solution. (Bromodifluoromethyl)trimethylsilane (Me₃SiCF₂Br)^{17a} and compounds **4a–d**,^{20a} were prepared according to literature procedures.


Scheme 3. Side Reaction



Scheme 4. Reaction of Substrate 1m



Scheme 5. Synthesis of Heterocycles



Reactions of Silyl Enol Ethers 4a–d (General Procedure 1).

Me₃SiCF₂Br (305 mg, 1.5 mmol, 1.5 equiv) and Bu₄NBr (64.5 mg, 0.2 mmol, 0.2 equiv) were added to a solution of silyl enol ether 4 (1 mmol, 1 equiv) in MeCN (1 mL) at room temperature, and the mixture was stirred for 1.5 h at 80 °C. Then the mixture was cooled to room temperature, NBS or NIS (1.3 mmol, 1.3 equiv) was added, and the mixture was stirred for 10 min at room temperature. For the workup, the mixture was diluted with water (8 mL), and the aqueous phase was extracted with hexane (3 × 5 mL). The combined organic layers were filtered through Na₂SO₄ and concentrated under vacuum, and the residue was purified by column chromatography.

Reactions of Ketones 1a–h,il (General Procedure 2).

Preparation of Silyl Enol Ether. NaI (210 mg, 1.4 mmol, 1.4 equiv) was placed in a tube and dried under vacuum using a heat gun. After cooling to room temperature, the tube was filled with argon. Then, MeCN (1 mL), ketone 1 (1 mmol, 1 equiv), and Et₃N (152 mg, 1.5 mmol, 1.5 equiv) were successively added. The mixture was cooled with an ice/water bath, and Me₃SiCl (1.66 mL, 13 mmol, 1.3 equiv) was added at 0 °C. The cooling bath was removed, and the mixture was stirred for 12 h at room temperature. Then, volatile components were evaporated under vacuum [a vacuum of about 10–20 Torr was applied with heating in a water bath at about 50 °C]. The solid residue was washed with hexane (3 × 15 mL) [the hexane layers were decanted and filtered through a cotton plug]. The combined filtrates were concentrated under vacuum using a rotary evaporator, furnishing silyl enol ether which was used without purification.

Reaction of Silyl Enol Ethers. The crude silyl enol was transferred into a reaction tube, the tube was evacuated and filled with argon. Then,

MeCN (1 mL), Me₃SiCF₂Br (305 mg, 1.5 mmol, 1.5 equiv) and Bu₄NBr (64.5 mg, 0.2 mmol, 0.2 equiv) were successively added at room temperature. The mixture was stirred for 1.5 h at 80 °C (for substrates 1a–e,h,k,l) or 2.5 h at 70 °C (for substrates 1f,i,j), and then cooled to room temperature. NBS or NIS (1.3 mmol, 1.3 equiv) was added, and the mixture was stirred for 10 min at room temperature. For the workup, the mixture was diluted with water (8 mL), and the aqueous phase was extracted with hexane (3 × 5 mL). The combined organic layers were filtered through Na₂SO₄ and concentrated under vacuum, and the residue was purified by column chromatography.

3-Bromo-1-(4-bromophenyl)-2,2-difluoropropan-1-one (3a).

General procedure 1, yield 292 mg (89%). General procedure 2, yield 257 mg (78%). Colorless crystals. Mp 45–46 °C. *R_f* 0.39 (hexane/EtOAc, 8:1). ¹H NMR (300 MHz, CDCl₃) δ: 7.97 (d, 2H, *J* = 8.2 Hz), 7.66 (d, 2H, *J* = 8.2 Hz), 3.89 (t, 2H, *J*_{H–F} = 14.7 Hz). ¹³C{¹H} NMR (75 MHz, CDCl₃) δ: 28.9 (t, *J* = 28.1 Hz), 115.3 (t, *J* = 256.4 Hz), 130.3 (t, *J* = 3.4 Hz), 130.7, 131.7 (t, *J* = 3.4 Hz), 132.4, 186.9 (t, *J* = 31.0 Hz). ¹⁹F NMR (282 MHz, CDCl₃) δ: –100.5 (t, 2F, *J* = 14.7 Hz). Calcd for C₉H₇Br₂F₂O (327.95): C, 32.96; H, 1.84. Found: C, 32.93; H, 1.91.

3-Bromo-2,2-difluoro-1-(4-methoxyphenyl)propan-1-one (3b).

General procedure 1, yield 265 mg (95%). General procedure 2, yield 248 mg (89%). Colorless crystals. Mp 47–48 °C. *R_f* 0.36 (hexane/EtOAc, 8:1). ¹H NMR (300 MHz, CDCl₃) δ: 8.10 (d, *J* = 9.2 Hz, 1H), 6.96 (d, *J* = 9.2 Hz, 1H), 3.89 (t, *J*_{H–F} = 14.7 Hz, 2H), 3.88 (s, 3H). ¹³C{¹H} NMR (75 MHz, CDCl₃) δ: 29.7 (t, *J* = 28.2 Hz), 55.7, 114.3, 115.4 (t, *J* = 256.5 Hz), 124.4 (t, *J* = 3.3 Hz), 132.9 (t, *J* = 3.3 Hz), 165.0, 185.9 (t, *J* = 29.9 Hz). ¹⁹F NMR (282 MHz, CDCl₃) δ: –100.3 (t, 2F, *J* = 14.7 Hz). Calcd for C₁₀H₉BrF₂O₂ (279.08): C, 43.04; H, 3.25. Found: C, 42.74; H, 3.36.

2,2-Difluoro-3-iodo-1-(4-methoxyphenyl)propan-1-one (3c).

General procedure 1, yield 267 mg (82%). General procedure 2, yield 262 mg (80%). Colorless crystals. Mp 55–56 °C. *R_f* 0.33 (hexane/EtOAc, 8:1). ¹H NMR (300 MHz, CDCl₃) δ: 8.08 (d, *J* = 8.7 Hz, 2H), 6.95 (d, *J* = 8.8 Hz, 2H), 3.89 (s, 3H), 3.75 (t, *J*_{H–F} = 16.1 Hz, 2H). ¹³C{¹H} NMR (75 MHz, CDCl₃) δ: 1.3 (t, *J* = 27.6 Hz), 55.8, 114.3, 115.9 (t, *J* = 255.1 Hz), 124.4 (t, *J* = 3.0 Hz), 133.0 (t, *J* = 3.5 Hz), 165.0, 185.3 (t, *J* = 31.1 Hz). ¹⁹F NMR (300 MHz, CDCl₃) δ: –94.8 (t, 2F, *J* = 16.1 Hz). Calcd for C₁₀H₉F₂IO₂ (326.08): C, 36.83; H, 2.78. Found: C, 36.77; H, 2.90.

7-Bromo-6,6-difluoro-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-one (3d).

General procedure 1, yield 267 mg (97%). General procedure 2, yield 235 mg (85%). Yellow oil. *R_f* 0.32 (hexane/EtOAc, 8:1). ¹H NMR (300 MHz, CDCl₃) δ: 7.68 (d, *J* = 7.5 Hz, 1H), 7.49 (t, *J* = 7.5 Hz, 1H), 7.36 (t, *J* = 7.5 Hz, 1H), 7.26 (d, *J* = 7.5 Hz, 1H), 4.69–4.46 (m, 1H), 3.37 (dd, *J* = 16.5, 11.0 Hz, 1H), 2.94 (dd, *J* = 16.5, 7.3 Hz, 1H), 2.70–2.37 (m, 2H). ¹³C NMR (75 MHz, CDCl₃) δ: 30.8, 33.3 (t, *J* = 2.3 Hz), 49.5 (dd, *J* = 27.6, 23.0 Hz), 115.6 (dd, *J* = 253.4, 255.7 Hz), 127.3, 130.2, 130.3, 133.2, 134.3, 140.5, 191.3 (dd, *J* = 28.8, 31.1 Hz). ¹⁹F NMR (282 MHz, CDCl₃) δ: –99.3 (dd, *J* = 243.7, 6.4 Hz), –106.4 (dd, *J* = 243.7, 14.8 Hz). Calcd for C₁₁H₉BrF₂O (275.09): C, 48.03; H, 3.30. Found: C, 48.04; H, 3.31.

6,6-Difluoro-7-iodo-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-one (3e).

General procedure 1, yield 274 mg (85%). Yellow oil. *R_f* 0.30 (hexane/EtOAc, 8:1). ¹H NMR (300 MHz, CDCl₃) δ: 7.69 (d, *J* = 7.3 Hz, 1H), 7.48 (t, *J* = 7.3 Hz, 1H), 7.35 (t, *J* = 7.3 Hz, 1H), 7.24 (d, *J* = 7.3 Hz, 1H), 4.77–4.56 (m, 1H), 3.30–3.11 (m, 1H), 3.04–2.85 (m, 1H), 2.63–2.45 (m, 2H). ¹³C NMR (75 MHz, CDCl₃) δ: 27.0 (t, *J* = 24.2 Hz), 32.6, 35.4 (t, *J* = 4.6 Hz), 116.3 (t, *J* = 253.4 Hz), 127.2, 130.2, 130.3, 133.1, 134.2, 140.9, 190.0 (t, *J* = 27.0 Hz). ¹⁹F NMR (282 MHz, CDCl₃) δ: –95.1 (dd, *J* = 238.5, 6.3 Hz), –97.8 (dd, *J* = 238.5, 19.1 Hz). Calcd for C₁₁H₉F₂IO (322.09): C, 41.02; H, 2.82. Found: C, 41.11; H, 2.91.

2,2-Difluoro-3-iodocycloheptanone (3f).

General procedure 1, yield 219 mg (80%). General procedure 2, yield 210 mg (77%). Colorless oil. *R_f* 0.29 (hexane/EtOAc, 5:1). ¹H NMR (300 MHz, CDCl₃) δ: 4.32 (dddd, *J*_{H–F} = 21.1 Hz, *J* = 8.3, 4.1, 2.3 Hz), 2.94–2.74 (m, 1H), 2.73–2.53 (m, 1H), 2.43–2.26 (m, 1H), 2.25–2.06 (m, 1H), 1.96–1.66 (m, 3H), 1.58 (m, 1H). ¹³C NMR (75 MHz, CDCl₃) δ: 22.0, 26.6 (dd, *J* = 26.1, 23.9 Hz), 27.0, 36.1 (t, *J* = 2.8 Hz), 38.3, 116.2 (dd, *J* = 255.6, 254.4 Hz), 197.9 (dd, *J* = 29.0, 26.5 Hz). ¹⁹F NMR (282 MHz, CDCl₃) δ:

–92.47 (d, $J = 241.6$ Hz), –110.04 (dd, $J = 241.6, 21.1$ Hz). Calcd for $C_9H_9F_2O$ (274.05): C, 30.68; H, 3.31. Found: C, 30.51; H, 3.19.

3-Bromo-2,2-difluoro-1-phenylpropan-1-one (3g).²³ General procedure 2, yield 229 mg (92%). Colorless oil. R_f 0.33 (hexane/EtOAc, 25:1). 1H NMR (300 MHz, $CDCl_3$) δ : 8.11 (d, $J = 8.2$ Hz, 2H), 7.66 (t, $J = 7.3$ Hz, 1H), 7.51 (t, $J = 7.7$ Hz, 2H), 3.91 (t, $J_{H-F} = 14.7$ Hz, 2H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ : 29.2 (t, $J = 27.6$ Hz), 115.3 (t, $J = 256.5$ Hz), 128.9, 130.3 (t, $J = 3.3$ Hz), 131.7 (t, $J = 3.2$ Hz), 134.9, 187.7 (t, $J = 30.4$ Hz). ^{19}F NMR (282 MHz, $CDCl_3$) δ : –100.6 (t, $J = 14.7$ Hz). Calcd for $C_9H_7BrF_2O$ (249.05): C, 43.40; H, 2.83. Found: C, 43.27; H, 2.71.

3-Bromo-1-(2,4-dimethylphenyl)-2,2-difluoropropan-1-one (3h). General procedure 2, yield 180 mg (65%). Colorless crystals. Mp 38–37 °C. R_f 0.32 (hexane/EtOAc, 12:1). 1H NMR (300 MHz, $CDCl_3$) δ : 7.81 (d, $J = 8.2$ Hz, 1H), 7.17–7.05 (m, 2H), 3.89 (t, $J_{H-F} = 13.7$ Hz, 2H), 2.48 (s, 3H), 2.38 (s, 3H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ : 21.3, 21.7, 29.2 (t, $J = 29.3$ Hz), 115.2 (t, $J = 258.2$ Hz), 126.4, 129.1, 130.2 (t, $J = 5.7$ Hz), 133.2, 141.1, 144.0, 190.4 (t, $J = 28.7$ Hz). ^{19}F NMR (282 MHz, $CDCl_3$) δ : –100.2 (t, $J = 13.7$ Hz). Calcd for $C_{11}H_{11}BrF_2O$ (277.11): C, 47.68; H, 4.00. Found: C, 47.54; H, 3.91.

3-Bromo-2,2-difluoro-1-(4-nitrophenyl)propan-1-one (3i). The reaction of 4-nitroacetophenone **1g** was performed according to General procedure 2 using modified conditions at the difluorocyclopropanation step: Me_3SiCF_2Br (406 mg, 2 mmol, 2 equiv), Bu_4NBr (96 mg, 0.3 mmol, 0.3 equiv), heating for 2 h at 80 °C. The crude material was separated by column chromatography (hexane/EtOAc, gradient from 4:1 to 2:1) affording compounds **3i** (172 mg) and **6a** (23 mg). Compound **3i** was subsequently distilled in a short path apparatus at 139–141 °C (bath temp)/0.7 Torr furnishing 165 mg (56%). Colorless oil. R_f 0.31 (hexane/EtOAc, 2:1). 1H NMR (300 MHz, $CDCl_3$) δ : 8.34 (d, $J = 8.5$ Hz, 2H), 8.25 (d, $J = 8.5$ Hz, 2H), 3.91 (t, $J_{H-F} = 14.7$ Hz, 2H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ : 28.2 (t, $J = 28.1$), 115.1 (t, $J = 256.4$ Hz), 124.0, 131.3 (t, $J = 3.4$ Hz), 136.1, 151.2, 186.6 (t, $J = 32.1$ Hz). ^{19}F NMR (282 MHz, $CDCl_3$) δ : –100.5 (t, $J = 14.7$ Hz). Calcd for $C_9H_6BrF_2NO_3$ (294.05): C, 36.76; H, 2.06; N, 4.76; Found: C, 36.82; H, 2.09; N, 4.74.

3-Bromo-2,2-difluoro-1-(naphthalen-2-yl)propan-1-one (3j). General procedure 2, yield 272 mg (91%). Colorless crystals. Mp 61–65 °C. R_f 0.30 (hexane/EtOAc, 8:1). 1H NMR (300 MHz, $CDCl_3$) δ : 8.72 (s, 1H), 8.08 (d, $J = 8.2$ Hz, 1H), 8.00 (d, $J = 8.2$ Hz, 1H), 7.97–7.84 (m, 2H), 7.76–7.52 (m, 2H), 3.99 (t, $J_{H-F} = 14.6$ Hz, 2H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ : 20.5 (t, $J = 28.1$ Hz), 115.5 (t, $J = 256.4$ Hz), 124.7, 124.8, 127.3, 128.0, 128.9, 130.0, 130.3, 132.4, 133.2 (t, $J = 4.6$ Hz), 136.3, 187.6 (t, $J = 30.4$ Hz). ^{19}F NMR (282 MHz, $CDCl_3$) δ : –99.9 (t, $J = 14.6$ Hz). Calcd for $C_{13}H_9BrF_2O$ (299.11): C, 52.20; H, 3.03. Found: C, 52.11; H, 2.98.

2,2-Difluoro-3-iodo-1-(naphthalen-2-yl)propan-1-one (3k). General procedure 2, yield 311 mg (90%). Colorless crystals. Mp 73–74 °C. R_f 0.29 (hexane/EtOAc, 16:1). 1H NMR (300 MHz, $CDCl_3$) δ : 8.69 (s, 1H), 8.08 (d, $J = 8.7$ Hz, 1H), 7.98 (d, $J = 8.1$ Hz, 1H), 7.94–7.83 (m, 2H), 7.70–7.57 (m, 2H), 3.84 (t, $J_{H-F} = 16.1$ Hz, 2H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ : 1.2 (t, $J = 27.6$ Hz), 115.9 (t, $J = 255.4$ Hz), 142.7 (t, $J = 2.2$ Hz), 127.2, 127.9, 128.6 (t, $J = 2.8$ Hz), 128.8, 129.7, 130.2, 132.3, 133.1 (t, $J = 5.0$ Hz), 136.2, 186.8 (t, $J = 31.0$ Hz). ^{19}F NMR (282 MHz, $CDCl_3$) δ : –94.4 (t, $J = 16.1$ Hz). Calcd for $C_{13}H_9F_2IO$ (346.11): C, 45.11; H, 2.62. Found: C, 45.12; H, 2.51.

3-Bromo-2,2-difluoro-1-phenylbutan-1-one (3l). General procedure 2, yield 182 mg (69%). Colorless oil. R_f 0.32 (hexane/EtOAc, 20:1). 1H NMR (300 MHz, $CDCl_3$) δ : 8.09 (d, $J = 7.8$ Hz, 2H), 7.66 (t, $J = 7.8$ Hz, 1H), 7.51 (t, $J = 7.8$ Hz, 2H), 4.64 (ddq, $J_{H-F} = 14.7$ Hz, $J = 11.0, 6.4$ Hz, 1H), 1.84 (d, $J = 6.4$ Hz, 3H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ : 18.5 (t, $J = 3.4$ Hz), 43.6 (dd, $J = 25.2, 26.7$ Hz), 116.3 (t, $J = 258.7$ Hz), 129.0, 130.2 (t, $J = 3.4$ Hz), 132.6, 134.6, 188.5 (dd, $J = 28.7, 31.0$ Hz). ^{19}F NMR (282 MHz, $CDCl_3$) δ : –103.8 (dd, $J = 277.1, 11.0$ Hz), –108.1 (dd, $J = 276.1, 14.7$ Hz). Calcd for $C_{10}H_9BrF_2O$ (263.08): C, 45.65; H, 3.45. Found: C, 45.59; H, 3.37.

3-Bromo-2,2-difluoro-1-(4-methoxyphenyl)-3-methylbutan-1-one (3m). General procedure 2, yield 218 mg (71%). Colorless oil. R_f 0.27 (hexane/EtOAc, 20:1). 1H NMR (300 MHz, $CDCl_3$) δ : 8.14 (d, $J = 8.4$ Hz, 2H), 6.95 (d, $J = 9.2$ Hz, 2H), 3.89 (s, 3H), 1.98 (s, 6H). $^{13}C\{^1H\}$

NMR (75 MHz, $CDCl_3$) δ : 28.8 (t, $J = 2.8$ Hz), 55.7, 60.9 (t, $J = 25.2$ Hz), 114.0, 117.5 (t, $J = 261.7$ Hz), 126.7 (t, $J = 2.3$ Hz), 133.3 (t, $J = 4.6$ Hz), 164.6, 187.0. ^{19}F NMR (282 MHz, $CDCl_3$) δ : –103.1 (s). Calcd for $C_{12}H_{13}BrF_2O_2$ (307.13): C, 46.93; H, 4.27. Found: C, 46.84; H, 4.23.

5-(tert-Butyl)-2,2-difluoro-3-iodocycloheptanone (3n). Mixture of diastereoisomers, 5:1. General procedure 2, yield 251 mg (76%). Colorless oil. R_f 0.28 (hexane/EtOAc, 15:1). 1H NMR (300 MHz, $CDCl_3$) δ : 4.74–4.58 (m, major) and 4.19–3.98 (m, minor) (1H), 3.06–2.41 (m) and 2.35–2.15 (m) (3H), 2.11–1.77 (m) and 1.69–1.33 (m) (4H), 0.92 (s, major) and 0.88 (s, minor) (9H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ : Major: 24.2 (d, $J = 2.8$ Hz), 27.0 (t, $J = 25.7$ Hz), 27.6, 33.6, 35.8 (dd, $J = 4.6, 1.8$ Hz), 38.5 (t, $J = 1.7$ Hz), 46.9, 116.1 (dd, $J = 256.5, 254.1$ Hz), 197.4 (dd, $J = 27.9, 24.6$); Minor: 24.3 (d, $J = 2.8$ Hz), 27.9 (dd, $J = 25.7, 23.7$ Hz), 21.2, 34.2, 37.6 (t, $J = 1.7$ Hz), 39.9 (d, $J = 5.2$ Hz), 50.8. ^{19}F NMR (282 MHz, $CDCl_3$) δ : Major: –99.9 (dd, 1F, $J = 250.0, 4.2$ Hz), –101.4 (dd, 1F, $J = 250.0, 10.6$ Hz); Minor: –89.9 (d, $J = 231.5$ Hz), –114.2 (dd, $J = 231.5, 29.0$ Hz). Calcd for $C_{11}H_{17}F_2IO$ (330.15): C, 40.02; H, 5.19. Found: C, 39.97; H, 5.02.

3-Bromo-2,2-difluorocyclotridecanone (3o). General procedure 2, yield 299 mg (96%). Colorless crystals. Mp 35.5–36.5 °C. R_f 0.29 (hexane/EtOAc, 30:1). 1H NMR (300 MHz, $CDCl_3$) δ : 4.28–4.04 (m, 1H), 3.00 (ddt, $J = 19.2, 10.1, 2.8$ Hz, 1H), 2.63 (ddd, $J = 19.2, 7.3, 2.8$ Hz, 1H), 2.01–1.82 (m, 1H), 1.83–1.51 (m, 4H), 1.50–1.05 (m, 13H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ : 21.2, 23.2, 23.9, 24.2, 24.6, 24.7, 25.5, 26.4, 30.6 (d, $J = 2.7$ Hz), 36.6, 51.1 (dd, $J = 24.0, 22.2$ Hz), 115.1 (dd, $J = 260.4, 255.3$ Hz), 201.2 (dd, $J = 32.1, 25.8$ Hz). ^{19}F NMR (282 MHz, $CDCl_3$) δ : –96.7 (d, $J = 243.7$ Hz), –125.3 (dd, $J = 243.7, 25.4$ Hz). Calcd for $C_{13}H_{21}BrF_2O$ (311.21): C, 50.17; H, 6.80. Found: C, 50.14; H, 6.96.

2,3-Dibromo-2-fluoro-1-(4-nitrophenyl)propan-1-one (6a). Obtained in the reaction of 4-nitroacetophenone **1g** as a byproduct to **3i** (see procedure for the synthesis of **3i**). Yield 23 mg (7%). Colorless crystals. Mp 88–89 °C. R_f 0.23 (hexane/EtOAc, 4:1). 1H NMR (300 MHz, $CDCl_3$) δ : 8.36–8.32 (m, 2H), 8.31–8.25 (m, 2H), 4.47 (dd, $J_{H-F} = 29.7, 11.7$ Hz, 1H), 4.20 (dd, $J = 11.7, 8.1$ Hz, 1H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ : 33.7 (d, $J = 22.7$ Hz), 98.2 ($J = 276$ Hz), 123.9, 131.6 (d, $J = 5.9$ Hz), 136.8, 150.9, 187.8 (d, $J = 27.9$ Hz). ^{19}F NMR (282 MHz, $CDCl_3$) δ : –121.7 (dd, $J = 29.7, 8.1$ Hz). Calcd for $C_9H_6Br_2FNO_3$ (354.96): C, 30.45; H, 1.70; N, 3.95. Found: C, 30.30; H, 1.81; N, 3.88.

Preparation of Compounds 5m and 7. Silyl enol ether **4m** was prepared according to General Procedure 2 from deoxybenzoine **1m** (268 mg, 1 mmol). A solution of crude **4m** in MeCN (1 mL) was treated with Me_3SiCF_2Br (609 mg, 3 mmol, 3 equiv) and Bu_4NBr (128 mg, 0.4 mmol, 0.4 equiv) which were successively added at room temperature. The mixture was heated at reflux for 10 h and then cooled to room temperature. For the workup, the mixture was diluted with water (8 mL), and the aqueous phase was extracted with hexane (3 \times 5 mL). The combined organic layers were filtered through Na_2SO_4 and concentrated under vacuum. The residue was separated by semipreparative HPLC (reversed phase column C18-reprosil ultra, 10 μ , 21 mm \times 250 mm, $H_2O/MeCN$ gradient 30/70 to 70/30). Retention time: **5m**, 9 min; **7**, 12 min.

(Z)-2-Fluoro-1,3-diphenylprop-2-en-1-one (5m).²² Yield 149 mg (66%). Colorless oil. 1H NMR (300 MHz, $CDCl_3$) δ : 7.98–7.36 (m, 10 H), 6.86 (d, $J_{H-F} = 36.7$ Hz, 1H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ : 120.2 (d, $J = 5.7$ Hz), 128.6, 129.0, 129.5 (d, $J = 3.5$ Hz), 130.1 (d, $J = 3.5$ Hz), 130.8 (d, $J = 9.2$ Hz), 131.5 (d, $J = 4.6$ Hz), 133.0, 136.4, 154.6 (d, $J = 271.9$ Hz), 188.0 (d, $J = 28.7$ Hz). ^{19}F NMR (282 MHz, $CDCl_3$) δ : –120.1 (d, $J = 36.7$ Hz). Calcd for $C_{15}H_{11}FO$ (226.25): C, 79.63; H, 4.90. Found: C, 79.67; H, 4.87.

((Z)-1-[Bromo(difluoro)methyl]-2-fluoro-1,3-diphenylprop-2-enyl)oxy(trimethyl)silane (7). Yield 58 mg (14%). Yellow oil. 1H NMR (300 MHz, $CDCl_3$) δ : 7.75–7.65 (m, 2H), 7.57 (d, $J = 7.3$ Hz, 2H), 7.47–7.29 (m, 7H), 6.27 (d, $J_{H-F} = 39.6$ Hz), 0.24 (s, 9H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ : 1.6 (d, $J = 1.6$ Hz), 84.6 (m), 111.9 (dt, $J = 6.9, 2.3$ Hz), 125.7 (m), 128.17, 128.23 (t, $J = 1.9$ Hz), 128.4 (d, $J = 2.3$ Hz), 128.8, 129.3 (d, $J = 8.0$ Hz), 129.5, 132.3 (d, $J = 2.3$ Hz), 137.1, 155.4 (d, $J = 269.6$ Hz). ^{19}F NMR (282 MHz, $CDCl_3$) δ : –53.3 (dd, $J = 162.4, 13.1$ Hz), –54.74 (dd, $J = 162.4, 4.2$ Hz), –111.0 (dd, $J = 39.6,$

13.1 Hz). Calcd for $C_{19}H_{20}BrF_3OSi$ (429.35): C, 53.15; H, 4.70. Found: C, 53.01; H, 4.71.

4,4-Difluoro-3-(4-methoxyphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole (8). Phenylhydrazine (108 mg, 1.05 mmol, 1.05 equiv) and potassium acetate (300 mg, 3 mmol, 3 equiv) were added to a solution of ketone **3b** (279 mg, 1 mmol, 1 equiv) in methanol (1.5 mL), and the mixture was stirred for 12 h at room temperature. Then, water (9 mL) was added with stirring, and the mixture was kept without stirring for an additional 10 min. The precipitate was filtered, washed with cold ethanol, and dried under vacuum. Yield 274 mg (95%). Yellow crystals. Mp 105–106 °C (dec.). 1H NMR (300 MHz, $CDCl_3$) δ : 7.86 (d, $J = 8.8$ Hz, 2H), 7.35 (d, $J = 8.1$ Hz, 2H), 7.15 (d, $J = 8.1$ Hz, 2H), 7.04–6.92 (m, 3H), 4.24 (t, $J_{H-F} = 21.9$ Hz, 2H), 3.86 (s, 3H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ : 55.5, 56.7 (t, $J = 31.0$ Hz), 113.0, 114.5, 121.0, 127.4, 128.4 (t, $J = 249.4$ Hz), 129.5, 141.5 (t, $J = 24.1$ Hz), 141.8, 143.6, 160.6. ^{19}F NMR (282 MHz, $CDCl_3$) δ : –92.7 (t, $J = 21.9$ Hz). Calcd for $C_{16}H_{14}F_2N_2O$ (288.29): C, 66.66; H, 4.89; N, 9.72. Found: C, 66.64; H, 4.90; N, 9.68.

4-Fluoro-3-(4-methoxyphenyl)-1-phenyl-1H-pyrazole (9). Phenylhydrazine (108 mg, 1.05 mmol, 1.05 equiv) and K_2CO_3 (300 mg, 3 mmol, 3 equiv) were added to a solution of ketone **3b** (279 mg, 1 mmol, 1 equiv) in DMF (1.5 mL), and the mixture was stirred for 12 h at room temperature and for 1 h at 130 °C. The mixture was cooled to room temperature, diluted with water (9 mL), and extracted with diethyl ether (3 \times 4 mL). The combined organic layers were filtered through Na_2SO_4 and concentrated under vacuum, and the residue was purified by column chromatography. Yield 244 mg (91%). Colorless crystals. Mp 102–103 °C. R_f 0.27 (hexane/EtOAc, 7:1). 1H NMR (300 MHz, $CDCl_3$) δ : 7.94 (d, $J = 8.7$ Hz, 2H), 7.85 (d, $J_{H-F} = 4.6$ Hz, 1H), 7.71 (d, $J = 7.6$ Hz, 2H), 7.47 (t, $J = 7.6$, 2H), 7.30 (t, $J = 7.6$, 1H), 7.02 (t, $J = 8.7$ Hz, 2H), 3.87 (s, 3H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ : 55.4, 114.1 (d, $J = 29.8$ Hz), 114.2, 118.5, 123.6 (d, $J = 3.4$ Hz), 126.4, 127.7 (d, $J = 3.4$ Hz), 129.5, 139.0 (d, $J = 6.9$ Hz), 140.2, 148.8 (d, $J = 252.4$ Hz), 159.8. ^{19}F NMR (282 MHz, $CDCl_3$) δ : –173.6 (d, $J = 4.6$ Hz). Calcd for $C_{16}H_{13}FN_2O$ (268.29): C, 71.63; H, 4.88; N, 10.44. Found: C, 71.48; H, 4.77; N, 10.34.

3-Bromo-2,2-difluoro-1-(4-methoxyphenyl)propan-1-ol (10a). $NaBH_4$ (57 mg, 1.5 mmol, 3 equiv) was added to a solution of ketone **3b** (140 mg, 0.5 mmol, 1 equiv) in ethanol (5 mL), and the mixture was stirred for 3 h at room temperature. The reaction was quenched by addition of saturated aqueous NH_4Cl (6 mL), and the mixture was concentrated under vacuum to one-third of its volume. The resulting mixture was diluted with water (3 mL) followed by extraction with methyl *tert*-butyl ether (3 \times 4 mL). The combined organic layers were filtered through Na_2SO_4 and concentrated under vacuum, and the residue was purified by column chromatography. Yield 125 mg (89%). Colorless oil. 1H NMR (300 MHz, $DMSO-d_6$) δ : 7.34 (d, $J = 8.5$ Hz, 2H), 6.93 (d, $J = 8.5$ Hz, 2H), 6.39 (d, $J = 5.8$ Hz, 1H), 4.92 (dt, $J_{H-F} = 16.4$, 5.8 Hz, 2H), 4.05–3.77 (m, 2H), 3.75 (s, 3H). $^{13}C\{^1H\}$ NMR (75 MHz, $DMSO-d_6$) δ : 31.3 (dd, $J = 29.8$, 26.4 Hz), 55.1, 71.7 (dd, $J = 29.8$, 25.2 Hz), 113.4, 119.4 (dd, $J = 248.4$, 245.0 Hz), 128.9, 129.4, 159.3. ^{19}F NMR (282 MHz, $DMSO-d_6$) δ : –107.7 (ddt, 1F, $J = 241.7$, 23.3, 8.5 Hz), –112.9 (dddd, 1F, $J = 241.7$, 38.1, 16.4, 5.8 Hz). Calcd for $C_{10}H_{11}BrF_2O_2$ (281.09): C, 42.73; H, 3.94. Found: C, 42.75; H, 4.04.

4-Bromo-3,3-difluoro-2-(4-methoxyphenyl)butan-2-ol (10b). $MeMgBr$ (3 M in diethyl ether, 400 μ L, 1.5 mmol, 1.5 equiv) was added dropwise to a solution of ketone **3b** (279 mg, 1 mmol, 1 equiv) in THF (400 μ L) at 0 °C. The cooling bath was removed, and the mixture was stirred for 30 min. The reaction was quenched by the addition of saturated aqueous NH_4Cl (3 mL) by extraction with diethyl ether (3 \times 4 mL). The combined organic layers were filtered through Na_2SO_4 and concentrated under vacuum, and the residue was purified by column chromatography. Yield 236 mg (80%). Colorless crystals. 70–71 °C. R_f 0.29 (hexane/EtOAc, 5:1). 1H NMR (300 MHz, $CDCl_3$) δ : 7.45 (d, $J = 8.7$ Hz, 2H), 6.90 (d, $J = 8.7$ Hz, 2H), 3.81 (s, 3H), 3.78 (dddd, $J_{H-F} = 29.0$ Hz, $J = 12.4$, 3.0, 0.8 Hz, 2H), 3.19 (dddd, $J_{H-F} = 29.0$, 12.4, 3.0, 0.8 Hz, 1H), 2.31 (s, 1H), 1.75 (s, 3H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ : 24.4 (t, $J = 2.8$ Hz), 30.4 (t, $J = 26.5$ Hz), 55.4, 76.0 (dd, $J = 26.9$, 26.0 Hz), 114.0, 120.0 (t, $J = 251.0$ Hz), 127.2, 132.2 (d, $J = 3.3$ Hz), 159.6. ^{19}F NMR (282 MHz, $CDCl_3$) δ : –111.6 (dd, 1F, $J = 243.7$, 29.0 Hz),

–114.9 (dd, 1F, $J = 243.7$, 29.0 Hz). Calcd for $C_{11}H_{13}BrF_2O_2$ (295.12): C, 44.77; H, 4.44. Found: C, 44.67; H, 4.46.

Synthesis of Oxetanes 11a,b. K_2CO_3 (336 mg, 3 mmol, 3 equiv) was added to a solution of alcohol **10** (1 mmol, 1 equiv) in DMF (2 mL) at room temperature, and the mixture was stirred for 4 h at 90 °C. The mixture was cooled to room temperature, diluted with water (8 mL), and extracted with diethyl ether (3 \times 4 mL). The combined organic layers were filtered through Na_2SO_4 and concentrated under vacuum, and the residue was purified by column chromatography.

3,3-Difluoro-2-(4-methoxyphenyl)oxetane (11a). Yield 157 mg (78%). Colorless oil. R_f 0.29 (hexane/EtOAc, 5:1). 1H NMR (300 MHz, $CDCl_3$) δ : 7.35 (d, $J = 9.2$ Hz, 2H), 6.96 (d, $J = 9.2$ Hz, 2H), 5.80 (t, $J_{H-F} = 11.0$ Hz, 1H), 5.01–4.75 (m, 2H), 3.83 (s, 3H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ : 55.4, 78.7 (dd, $J = 26.4$, 24.1 Hz), 91.7 (dd, $J = 26.4$, 23.0 Hz), 114.1, 118.0 (dd, $J = 282.3$, 280.0 Hz), 125.7 (t, $J = 2.9$ Hz), 128.6, 160.6. ^{19}F NMR (282 MHz, $CDCl_3$) δ : –99.5 (dq, $J = 192.9$, 11.0 Hz, 1F), –112.4 (ddt, $J = 192.9$, 17.1, 11.0 Hz, 1F). Calcd for $C_{10}H_{10}F_2O_2$ (200.18): C, 60.00; H, 5.04. Found: C, 59.84; H, 4.92.

3,3-Difluoro-2-(4-methoxyphenyl)-2-methyloxetane (11b). Yield 158 mg (74%). Colorless oil. R_f 0.33 (hexane/EtOAc, 4:1). 1H NMR (300 MHz, $CDCl_3$) δ : 7.36 (d, $J = 8.7$ Hz, 2H), 6.95 (d, $J = 8.7$ Hz, 2H), 4.88–4.65 (m, 2H), 3.83 (s, 3H), 1.77 (s, 3H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ : 23.2, 55.4, 76.5 (t, $J = 26.0$ Hz), 95.2 (t, $J = 23.2$ Hz), 113.9, 118.6 (dd, $J = 284.4$, 282.6 Hz), 126.4, 131.2, 159.6. ^{19}F NMR (282 MHz, $CDCl_3$) δ : –108.3 (dt, $J = 187.5$, 12.7 Hz, 1F), –113.5 (dt, $J = 187.5$, 12.7 Hz, 1F). Calcd for $C_{11}H_{12}F_2O_2$ (214.21): C, 61.68; H, 5.65. Found: C, 61.76; H, 5.71.

■ ASSOCIATED CONTENT

📄 Supporting Information

Copies of NMR spectra for all compounds. The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.5b00904.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: adil25@mail.ru.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was supported by the Ministry of Science (Project MD-3256.2015.3), Russian Foundation for Basic Research (Projects 15-33-20133, 14-03-00293), and the Russian Academy of Sciences.

■ REFERENCES

- (a) *Fluorine in Medicinal Chemistry and Chemical Biology*; Ojima, I., Ed.; John Wiley & Sons: Chichester, 2009. (b) Begue, J.-P.; Bonnet-Delpon, D. *Bioorganic and Medicinal Chemistry of Fluorine*; Wiley-VCH, Weinheim, 2008.
- (a) Gelb, M. H.; Svaren, J. P.; Abeles, R. H. *Biochemistry* **1985**, *24*, 1813–1817. (b) Silva, A. M.; Cachau, R. E.; Sham, H. L.; Erickson, J. W. *J. Mol. Biol.* **1996**, *255*, 321–340. (c) Schirlin, D.; Baltzer, S.; Altenburger, J. M.; Tarnus, C.; Remy, J. M. *Tetrahedron* **1996**, *52*, 305–318. (d) Han, C.; Salyer, A. E.; Kim, E. H.; Jiang, X.; Jarrard, R. E.; Powers, M. S.; Kirchoff, A. M.; Salvador, T. K.; Chester, J. A.; Hockerman, G. H.; Colby, D. A. *J. Med. Chem.* **2013**, *56*, 2456–2465. (e) Ginzburg, R.; Ambizas, E. M. *Expert Opin. Drug Metab. Toxicol.* **2008**, *4*, 1091–1097.
- (a) Codelli, J. A.; Baskin, J. M.; Agard, N. J.; Bertozzi, C. R. *J. Am. Chem. Soc.* **2008**, *130*, 11486–11493. (b) O'Hagan, D.; Wang, Y.; Skibinski, M.; Slawin, A. M. Z. *Pure Appl. Chem.* **2012**, *84*, 1587–1595.
- (a) Yang, M.-H.; Orsi, D. L.; Altman, R. A. *Angew. Chem., Int. Ed.* **2015**, *54*, 2361–2365. (b) Ge, S.; Chaladaj, W.; Hartwig, J. F. *J. Am. Chem. Soc.* **2014**, *136*, 4149–4152. (c) Guo, C.; Wang, R.-W.; Qing, F.-L. *J. Fluorine Chem.* **2012**, *143*, 135–142. (d) Han, C.; Kim, E. H.; Colby,

- D. A. *J. Am. Chem. Soc.* **2011**, *133*, 5802–5805. (e) Guo, Y.; Shreeve, J. M. *Chem. Commun.* **2007**, 3583–3585. (f) Uneyama, K.; Amii, H. *J. Fluorine Chem.* **2002**, *114*, 127–131. (g) Qiu, Z.-M.; Burton, D. J. *Tetrahedron Lett.* **1993**, *34*, 3239–3242.
- (5) (a) Peng, W.; Shreeve, J. M. *J. Org. Chem.* **2005**, *70*, 5760–5763. (b) Pravst, I.; Zupan, M.; Stavber, S. *Synthesis* **2005**, 3140–3146. (c) Differding, E.; Rüegg, G. M.; Lang, R. W. *Tetrahedron Lett.* **1991**, *32*, 1779–1782. (d) Stavber, S.; Zupan, M. *Synlett* **1996**, 693–694.
- (6) (a) Kosobokov, M. D.; Levin, V. V.; Struchkova, M. I.; Dilman, A. D. *Org. Lett.* **2015**, *17*, 760–763. (b) For a relevant work, see: Kageshima, Y.; Suzuki, C.; Oshiro, K.; Amii, H. *Synlett* **2015**, *26*, 63–66.
- (7) Kulinkovich, O. G. *Chem. Rev.* **2003**, *103*, 2597–2632.
- (8) For a recent application in process chemistry, see: Young, I. S.; Haley, M. W.; Tam, A.; Tymonko, S. A.; Xu, Z.; Hanson, R. L.; Goswami, A. *Org. Process Res. Dev.* **2015**, asap, DOI: 10.1021/op500135x.
- (9) (a) Raiman, M. V.; Pukin, A. V.; Tyvorskii, V. I.; Kimpe, N. D.; Kulinkovich, O. G. *Tetrahedron* **2003**, *59*, 5265–5272. (b) Kulinkovich, O. G.; Sviridov, S. V.; Vasilevskii, D. A. *Zh. Org. Khim.* **1991**, *27*, 1431–1433; *J. Org. Chem. USSR (Engl. Transl.)* **1991**, *27*, 1251–1253. (c) Markovic, M.; Duranova, M.; Koos, P.; Szolcsanyi, P.; Gracza, T. *Tetrahedron* **2013**, *69*, 4185–4189. (d) DePuy, C. H.; Arney, W. C.; Gibson, D. *J. Am. Chem. Soc.* **1968**, *90*, 1830–1840.
- (10) Gassen, K. R.; Bielefeldt, D.; Marhold, A.; Andres, P. J. *Fluorine Chem.* **1991**, *55*, 149–162.
- (11) (a) Yang, Z.-Y. *J. Org. Chem.* **2003**, *68*, 4410–4416. (b) Hung, M.-H.; Long, L.; Yang, Z.-Y. *J. Org. Chem.* **2004**, *69*, 198–201. (c) Yang, Z.-Y.; Krusic, P. J.; Smart, B. E. *J. Am. Chem. Soc.* **1995**, *117*, 5397–5398.
- (12) (a) Song, X.; Chang, J.; Zhu, D.; Li, J.; Xu, C.; Liu, Q.; Wang, M. *Org. Lett.* **2015**, *17*, 1712–1715. (b) Wu, S.-H.; Yu, Q. *Acta Chim. Sinica* **1989**, *7*, 253–257.
- (13) (a) The stability of compounds **2** depends on their structure. Cyclopropanes **2** derived from acetophenones are sensitive even to aqueous workup, while cyclopropanes **2** derived from cyclic ketones can be distilled under vacuum. (b) For similar instability of difluorinated cyclopropanols generated under basic conditions, see: Crabbe, P.; Cervantes, A.; Cruz, A.; Galeazzi, E.; Iriarte, J.; Velarde, E. *J. Am. Chem. Soc.* **1973**, *95*, 6655–6665. (c) Kobayashi, Y.; Taguchi, T.; Mamada, M.; Shimizu, H.; Murohashi, H. *Chem. Pharm. Bull.* **1979**, *27*, 3123–3129.
- (14) Ni, C.; Hu, J. *Synthesis* **2014**, *46*, 842–863.
- (15) (a) Li, L.; Wang, F.; Ni, C.; Hu, J. *Angew. Chem., Int. Ed.* **2013**, *52*, 12390–12394. (b) Wang, F.; Zhang, W.; Zhu, J.; Li, H.; Huang, K.-W.; Hu, J. *Chem. Commun.* **2011**, *47*, 2411–2413.
- (16) Tsybalya, A. V.; Kosobokov, M. D.; Levin, V. V.; Struchkova, M. I.; Dilman, A. D. *J. Org. Chem.* **2014**, *79*, 7831–7835.
- (17) For various applications of Me₃SiCF₂Br reported by our group, see: (a) Kosobokov, M. D.; Dilman, A. D.; Levin, V. V.; Struchkova, M. I. *J. Org. Chem.* **2012**, *77*, 5850–5855. (b) Levin, V. V.; Zemtsov, A. A.; Struchkova, M. I.; Dilman, A. D. *Org. Lett.* **2013**, *15*, 917–919. (c) Kosobokov, M. D.; Levin, V. V.; Zemtsov, A. A.; Struchkova, M. I.; Korlyukov, A. A.; Arkhipov, D. E.; Dilman, A. D. *Org. Lett.* **2014**, *16*, 1438–1441. (d) Kosobokov, M. D.; Levin, V. V.; Struchkova, M. I.; Dilman, A. D. *Org. Lett.* **2014**, *16*, 3784–3787. (e) Zemtsov, A. A.; Kondratyev, N. S.; Levin, V. V.; Struchkova, M. I.; Dilman, A. D. *J. Org. Chem.* **2014**, *79*, 818–822. (f) Smirnov, V. O.; Struchkova, M. I.; Arkhipov, D. E.; Korlyukov, A. A.; Dilman, A. D. *J. Org. Chem.* **2014**, *79*, 11819–11823.
- (18) (a) For complex formation between Br₂ and HMPA, see: Ozari, Y.; Jagur-Grodzinski, J. *J. Chem. Soc., Dalton Trans.* **1973**, 474–477. For complexes of N-halosuccinimides with Lewis basic molecules, see: (b) Castellote, I.; Moron, M.; Burgos, C.; Alvarez-Builla, J.; Martin, A.; Gomez-Sal, P.; Vaquero, J. J. *Chem. Commun.* **2007**, 1281–1283. (c) Raatikainen, K.; Rissanen, K. *CrystEngComm* **2011**, *13*, 6972–6977. (d) Wang, Y.; Chen, X.; Zou, J.; Yu, Q. *Chem. Res. Chinese U.* **2007**, *23*, 355–359.
- (19) The exchange of halogen X between Me₃SiCF₂X and halide ion (X = Cl, Br) was described; see: Wang, F.; Li, L.; Ni, C.; Hu, J. *Beilstein J. Org. Chem.* **2014**, *10*, 344–351.
- (20) (a) Cazeau, P.; Duboudin, F.; Moulines, F.; Babot, O.; Dunogues, J. *Tetrahedron* **1987**, *43*, 2075–2088. (b) Emde, H.; Domsch, D.; Feger, H.; Frick, U.; Götz, A.; Hergott, H. H.; Hofmann, K.; Kober, W.; Krägeloh, K.; Oesterle, T.; Steppan, W.; West, W.; Simchen, G. *Synthesis* **1982**, 1–26.
- (21) Oxetanes have recently emerged as valuable fragments in drug discovery, see: Burkhard, J. A.; Wuitschik, G.; Rogers-Evans, M.; Müller, K.; Carreira, E. M. *Angew. Chem., Int. Ed.* **2010**, *49*, 9052–9067.
- (22) Yamada, S.; Kato, M.; Komori, Y.; Konno, T.; Ishihara, T. *Org. Biomol. Chem.* **2011**, *9*, 5493–5502.
- (23) Chen, C.; Wilcoxon, K.; Zhu, Y.-F.; Kim, K.; McCarthy, J. R. *J. Org. Chem.* **1999**, *64*, 3476–3482.